Pachymic acid

小分子

茯苓酸

Q-100369 | Lanost-8-en-21-oic acid, 3-(acetyloxy)-16-hydroxy-24-methylene-, (3beta,16alpha)- | 3-O-Acetyltumulosic acid | CCRIS 7792 | NSC 244427 | BS-42182 | EBURICA-8,24(28)-DIEN-21-OIC ACID, 3.BETA.,16.ALPHA.-DIHYDROXY-, 3-ACETATE | LANOST-8-EN-21-OIC

Pachymic acid

P649133-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

Pachymic acid is a lanostrane-type triterpenoid from P. cocos . Pachymic acid inhibits Akt and ERK signaling pathways. In Vitro Pachymic acid (PA) is able to inhibit gallbladder cancer tumorigenesis involving affection of Akt and ERK signaling pathways. Pachymic acid (PA) treatment significantly inhibits Rho A, Akt and ERK pathway in gallbladder carcinoma cells. Pachymic acid (PA) treatment can dose-dependently downregulate PCNA, ICAM-1, RhoA, p-Akt and pERK. Cell growth is inhibited by 10 µg/mL Pachymic acid (PA) 12 h after treatment, and a concentration of 30 µg/mL further reduced cell growth. The growth of cells is suppressed in a time- and dose-dependent manner. After 48 h treatment, about 25%, 40% and 70% of the cell growth are inhibited by Pachymic acid (PA) at concentration of 10 µg/mL, 20 µg/mL and 30 µg/mL, respectively. Pachymic acid (PA) also inhibits the growth of gallbladder carcinoma cells in a time-dependent and dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo To evaluate the anti-tumor activity of Pachymic acid (PA) in vivo, human lung cancer NCI-H23 tumor xenograft models are used. Pachymic acid (PA) significantly suppresses tumor growth at doses of 30 and 60 mg/kg for 21 days compared with the control group. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal administration Mice Female athymic nude mice of 4-5 weeks of age are used. Exponentially growing NCI-H23 cells (5×10 6 in 100 µL PBS) are injected subcutaneously in the right flank of each mouse. Tumor xenografts are allowed to grow to an average size of 100-200 mm 3 and are randomly assigned to four different treatment groups (six mice per group): (a) vehicle control (0.1% DMSO in physiological saline); (b) Pachymic acid (PA) 10 mg/kg; (c) PA 30 mg/kg; (Dd) PA 60 mg/kg. The mice are administered PA via intraperitoneal (ip) injections for 3 weeks (5 days/week). Tumor size is measured on two axes with the aid of Vernier calipers and tumor volume (mm 3 ) is calculated. aladdin has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:ERK

茯苓酸是从茯苓中提取的一种羊毛甾烷型三萜类化合物。茯苓酸可抑制 Akt 和 ERK 信号通路。

29070-92-6

C33H52O5

528.76 g/mol

5484385

CC(C)C(=C)CC[C@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)OC(=O)C)C)C)C)O)C(=O)O

(2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid

1S/C33H52O5/c1-19(2)20(3)10-11-22(29(36)37)28-25(35)18-33(9)24-12-13-26-30(5,6)27(38-21(4)34)15-16-31(26,7)23(24)14-17-32(28,33)8/h19,22,25-28,35H,3,10-18H2,1-2,4-9H3,(H,36,37)/t22-,25-,26+,27+,28+,31-,32-,33+/m1/s1

VDYCLYGKCGVBHN-DRCQUEPLSA-N

CC(C)C(=C)CCC(C1C(CC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)OC(=O)C)C)C)C)O)C(=O)O

5484385

29070-92-6

pachymic acid

DMSO : 10 mg/mL (18.91 mM; ultrasonic and warming and heat to 60°C) Ethanol : 4.17 mg/mL (7.89 mM; Need ultrasonic) H2O : <0.1 mg/mL (insoluble)

2

5

8

528.381 Da

528.381 Da

83.800 Ų

38

0

1020.000

0

1

7.200